The News Review:

- Kurt Mussina and Jim Calvin join Trio Clinical Research Management …
- Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 …
- PAREXEL Receives BioSingapore Award for Best Performing CR
- Company Receives Federal Contract for Restoration of Damaged Muscle
- i3 launches new web-based clinical trial and data management …

Kurt Mussina and Jim Calvin join Trio Clinical Research Management …
PharmaLive.com (press release)
March 23 2009 – Trio Clinical Research a leading clinical research services company supporting the pharmaceutical biotechnology and medical device industry announced today the appointments of Kurt Mussina as Senior Vice President of Business Development and Jim Calvin as Senior Vice President of Clinical Services. Mussina has over 20 years of international biopharmaceutical business experience and a proven track record in building global sales and marketing organizations in the CR industry. His executive experience spans operating and technical functions as well as managing international sales teams responsible for annually delivering hundreds of millions of dollars in profitable contracts. Prior to joining Trio Clinical Research he served as Vice President Client Services at Aptuit; Vice President Global Clinical Business Development at Inveresk and Director of Sales and Marketing at AAI.

Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 …
FXBusiness
Eastern Time to discuss the results from this Phase IIa clinical trial. Robert Blum Cytokinetics’ President and Chief Executive fficer will be joined by Andrew Wolff MD FACC Cytokinetics’ Senior Vice President of Clinical Research and Development and Chief Medical fficer Fady Malik MD Cytokinetics’ Vice President of Muscle Biology and Cardiovascular Therapeutics and John R. Teerlink MD FACC FAHA FESC Professor of Medicine at the University of California San Francisco and the Director of Heart Failure at the San Francisco Veterans Affairs Medical Center in a discussion of the data. Blum will moderate the session.

PAREXEL Receives BioSingapore Award for Best Performing CR
FXBusiness
PAREXEL is recognized for the broad spectrum of services provided by the Company the competitive edge it has created in this geography and its international reputation for speed and high quality. “PAREXEL is honored to be chosen as the Best Performing CR by BioSingapore” said Mark A. Chief perating fficer of PAREXEL International.

Company Receives Federal Contract for Restoration of Damaged Muscle
WPI News
Joining the effort for the new phase of this work will be George Pins PhD associate professor of biomedical engineering at WPI who has pioneered novel cell-delivery strategies that will be useful for the project. The new phase also involves collaboration with the clinical research team led by Raymond Dunn MD professor of surgery and cell biology at the University of Massachusetts Medical School and chief of plastic and reconstructive surgery at UMass Memorial Medical Center. "This new award not only validates the important work CellThera and WPI are doing in the area of regenerative medicine but by bringing together basic science engineering and the clinical expertise of UMass along with the commercial strength in the Worcester region this work will help push the science closer to the clinic and closer to helping people recover from devastating injuries" said Eric W. verström PhD professor and head of WPI's Department of Biology and Biotechnology. The long-range goal of the DARPA program is to find ways to harness the body's natural regenerative abilities to heal wounds that involve bone muscle nerves and soft tissue. The impetus for the program is to develop new therapies for soldiers who return home from war with major injuries.

i3 launches new web-based clinical trial and data management …
Pharmaceutical Business Review
The company said that i3Cube also provides streamlined communication across the entire study team study-specific automated workflow and an integrated study library with version control including an electronic trial master file. Glenn Bilawsky CE of i3 said: “i3Cube was designed to provide our clients and clinical investigators with a simple easy-to-use and streamlined experience. We brought together our use of proprietary health care claims data with our clinical research expertise and developed i3Cube to create time and cost efficiencies for our customers. “i3 an Ingenix company provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It?s division include i3 Research i3 Drug Safety i3 Pharma Informatics i3 Statprobe i3 Pharma Resourcing and i3 Innovus.
Related from Managementmonster: CommVault Introduces Simpana 8 Next-Generation Data Management …